Cargando…

Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction

Detalles Bibliográficos
Autor principal:	Blair, Hannah A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748317/ https://www.ncbi.nlm.nih.gov/pubmed/34859355 http://dx.doi.org/10.1007/s40256-021-00512-7

Ejemplares similares

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Correction: Dapaglifozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling
por: Wu, Jinchun, et al.
Publicado: (2022)

Correction to: Structural and myocardial dysfunction in heart failure beyond ejection fraction
por: Severino, Paolo, et al.
Publicado: (2019)

Correction: Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort
Publicado: (2018)

Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations
por: Arvanitaki, Alexandra, et al.
Publicado: (2020)

Publisher Correction to: Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
Publicado: (2020)

Correction: Right atrial volume by cardiovascular magnetic resonance predicts mortality in patients with heart failure with reduced ejection fraction
Publicado: (2017)

Correction: Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Publicado: (2023)

Correction to: ‘Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction’
Publicado: (2023)

Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Publicado: (2013)

Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction
Publicado: (2017)

A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
por: Reed, Brent N, et al.
Publicado: (2015)

Author Correction: Deep learning of ECG waveforms for diagnosis of heart failure with a reduced left ventricular ejection fraction
por: Choi, JungMin, et al.
Publicado: (2022)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature
por: Techorueangwiwat, Chol, et al.
Publicado: (2021)

Prevalence of Symptomatic Heart Failure with Reduced and with Normal Ejection Fraction in an Elderly General Population–The CARLA Study
por: Tiller, Daniel, et al.
Publicado: (2013)

Correction: Prognostic value of left ventricular mitral annular longitudinal displacement obtained by tissue doppler imaging in patients with heart failure with reduced ejection fraction
Publicado: (2021)

Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN‐HF Registry
Publicado: (2020)

Correction to: Interleukin‐1β Disruption Protects Male Mice From Heart Failure With Preserved Ejection Fraction Pathogenesis
Publicado: (2023)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Updates in pharmacotherapy of heart failure with reduced ejection fraction
por: Espinoza, Clifton, et al.
Publicado: (2021)

Role of interleukins in heart failure with reduced ejection fraction
por: Segiet, Oliwia Anna, et al.
Publicado: (2019)

Editorial: Edema in heart failure with reduced ejection fraction
por: Gladysheva, Inna P., et al.
Publicado: (2023)

Heart Failure with Reduced Ejection Fraction: The Role of Cardiovascular and Lung Ultrasound beyond Ejection Fraction
por: Shahnazaryan, Syuzanna, et al.
Publicado: (2023)

Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021)

Heart Failure With Preserved Ejection Fraction vs. Reduced Ejection Fraction　― Mechanisms of Ventilatory Inefficiency During Exercise in Heart Failure ―
por: Tsujinaga, Shingo, et al.
Publicado: (2020)

Heart Failure with Reduced Ejection Fraction—Does Sex Matter?
por: Swaraj, Sascha, et al.
Publicado: (2021)

Myocardial Contraction Fraction is Superior to Ejection Fraction in Predicting Functional Capacity in Patients with Heart Failure with Reduced Ejection Fraction
por: Abdellatif, Yasser A., et al.
Publicado: (2022)

Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
por: Chaudhary, Ammar G., et al.
Publicado: (2021)

Correction to: Hexanic Extract of Serenoa repens (Permixon(®)): A Review in Symptomatic Benign Prostatic Hyperplasia
por: Blair, Hannah A.
Publicado: (2022)

Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
por: Egbuche, Obiora, et al.
Publicado: (2020)

Heart failure with reduced ejection fraction due topolycythemia vera
por: Zaman, Muhammad Omer, et al.
Publicado: (2021)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
por: Schäfer, Andreas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o7upm515qcuc9nj8vcjsage427